UNSPSC 51401513: Nitrazepam

This classification denotes a benzodiazepine with the molecular formula C15H11N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9CLV70W7HS, chemically known as 2,3-dihydro-7-nitro-5-phenyl-1h-1,4-benzodiazepin-2-on but generally known as nitrazepam, which bears US NIH Compound Identifier 4506. European Medicines Agency schedules Nitrazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09318MIG.

UNSPSC 51401513 Nitrazepam is a Commodity code that encompasses controlled pharmaceutical substances, but recent state and local procurement activity under this code shows minimal direct alignment — the three opportunities identified involve naloxone procurement, a request for information on direct-to-manufacturer prescription programs, and a cooperative multistate purchasing vehicle for generic pharmaceuticals and OTC products. State and local governments issue solicitations for pharmaceutical products through county health departments, state health and human services agencies, and cooperative purchasing organizations that bundle purchasing power across multiple jurisdictions. The Seminole County, Florida procurement exemplifies the direct-purchase model: the county's IFB sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries and a two-year initial term plus one-year renewal option. The scope of work varies — from point-of-use emergency pharmaceutical supplies (naloxone) to systemic pharmacy benefit program restructuring (Texas HHS's direct-to-manufacturer initiative) to cooperative framework agreements that establish pricing and terms for multi-jurisdiction access to generic pharmaceuticals.

Activity appears concentrated in Florida and Texas, with multistate cooperative purchasing mechanisms (MMCAP) serving participants in Minnesota and Oregon. Seminole County issued its IFB (60459723LAS) with a due date of July 26, 2023, and response deadline of July 26, 2023 at 2:00 pm. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026 to gather vendor capability information on direct-to-manufacturer prescription contracting models without formal competitive criteria or award amounts at that preliminary stage. MMCAP issued an RFP (S1070000015802) on January 20, 2026 with a response deadline of March 26, 2026, seeking generic pharmaceutical and OTC product manufacturers to supply through authorized wholesalers effective July 1, 2026, with evaluation weighted 75 percent on price competitiveness and 25 percent on administrative compliance and capability factors. These opportunities suggest limited recent activity specifically under the nitrazepam code itself, though pharmaceutical procurement broadly involves state health departments, counties, and regional cooperative purchasing vehicles.